Acorai was founded in 2019 with a simple but ambitious mission: to make hemodynamic insights non-invasive, accessible, and actionable for every healthcare professional caring for people with heart failure.

With a background in machine learning applied to time-series data in finance, Co-Founder & CEO Filip Peters saw the opportunity to transfer advanced analytical techniques into healthcare. After exploring several applications, the focus landed on heart failure, where the largest clinical unmet need is.

From early prototypes of our patented SAVE Sensor System—a novel integration of seismic, acoustic, visual, and electric sensing—to today’s handheld form factor, our focus has remained clear: providing accurate and absolute cardiac and pulmonary pressure insights without a catheter and translating that data into better decisions at the point of care.

Heart failure affects more than 60 million people worldwide, remains a leading cause of hospitalization in older adults, and imposes a massive economic burden with high readmission rates. By enabling earlier, more individualized therapy, more informed discharge decision-making and reducing avoidable admissions, Acorai has the potential to fundamentally improve outcomes and positively impact one of the world’s costliest disease areas.